Jeffrey Robert Ajer - May 2, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
May 2, 2024
Transactions value $
-$393,956
Form type
4
Date filed
5/6/2024, 04:40 PM
Previous filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock +Grant/Award $20,594 +300 +0.42% $68.65 71,767 Apr 30, 2024 Direct F1
transaction BMRN Common Stock -Sell -$414,550 -5,000 -6.97% $82.91 66,767 May 2, 2024 Direct F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on April 13, 2023.